文献速递淋巴瘤造血干细胞移植与细胞治疗

异基因造血干细胞移植用于未接受移植的霍奇金淋巴瘤患者:单臂多中心研究

Allo-HSCT in transplant-naïve patients with Hodgkin lymphoma: a single-arm, multicenter study.
PubMed 文献 · Blood Adv · 2019-01-01

该单臂多中心研究评估了异基因造血干细胞移植(allo-HSCT)在未接受过移植的复发/难治性霍奇金淋巴瘤(HL)患者中的作用,这些患者对1-2线挽救化疗未达到代谢完全缓解(mCR)。符合条件者为PET/CT评估有残留但非进展性疾病。主要终点3年无进展生存率为67.7%(95%CI 48.4%-81.2%),达到主要目标。

要点

  • 3年无进展生存率为67.7%,达到主要研究终点。
  • 移植前有残留代谢活性疾病者生存结局与整体相当。
  • 非复发死亡率为16.1%,复发率为18.7%。

核心结论

  • allo-HSCT在精选的高危HL患者中显示出令人鼓舞的结果,可能确立其潜在作用。

研究设计与样本

  • 单臂多中心研究,纳入未接受过移植的复发/难治性HL患者,对1-2线挽救化疗未达mCR,PET/CT评估有残留但非进展性疾病。
  • 预处理方案包括卡莫司汀、依托泊苷、阿糖胞苷、美法仑和阿仑单抗。

主要发现

  • 无移植失败,无4级急性GVHD;仅19.4%患者发生2-3级GVHD,22.2%发生广泛性慢性GVHD。
  • 非复发死亡率为16.1%(95%CI 7.1%-34.5%),复发率为18.7%(95%CI 8.2%-39.2%)。
  • 3年无进展生存率为67.7%(95%CI 48.4%-81.2%),达到主要目标。
  • 移植前有残留代谢活性疾病者(n=24,70.8%;95%CI 17.2%-83.7%)生存结局相当。
  • 5例复发患者中2例接受供者淋巴细胞输注(DLI)后维持mCR,3年总生存率为80.7%(95%CI 61.9%-90.8%)。

临床怎么用

  • 对于未接受过移植的复发/难治性HL患者,若对1-2线挽救化疗未达mCR但有残留非进展性疾病,可考虑allo-HSCT。
  • 预处理可采用卡莫司汀、依托泊苷、阿糖胞苷、美法仑和阿仑单抗方案。
  • 移植后混合嵌合或残留/复发疾病可给予DLI。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

We evaluated the role of allogeneic hematopoietic stem cell transplantation (allo-HSCT) in transplant-naïve patients with relapsed/refractory Hodgkin lymphoma (HL) who failed to attain metabolic complete response (mCR) to 1 to 2 lines of salvage chemotherapyThose with residual but nonprogressive disease assessed by positron emission tomography/computed tomography scanning were eligible. An additional 1 to 2 cycles of salvage therapy were permissible in those with progressive disease or when required to bridge to allo-HSCT, with additional imaging at baseline before transplantation. Conditioning consisted of carmustine, etoposide, cytarabine, melphalan, and alemtuzumab. Donor lymphocyte infusions (DLI) were administered for mixed chimerism or residual or relapsed disease. Eleven patients had sibling donors, 13 had HLA-matched unrelated donors, and 7 had HLA-mismatched unrelated donors. There were no graft failures, and no episodes of grade 4 acute graft-versus-host disease (GVHD); only 19.4% of patients had grade 2 to 3 GVHD, and 22.2% had extensive chronic GVHD. The non-relapse mortality rate was 16.1% (95% confidence interval [CI], 7.1%-34.5%). Relapse incidence was 18.7% (95% CI, 8.2%-39.2%). The study met its primary objective, with a 3-year progression-free survival of 67.7% (95% CI, 48.4%-81.2%). Survival outcomes were equivalent in those with residual metabolically active disease immediately before transplantation (n = 24 [70.8%; 95% CI, 17.2%-83.7%]). Two of the 5 patients who relapsed received DLI and remained in mCR at latest follow-up, with a 3-year overall survival of 80.7% (95% CI, 61.9%-90.8%). We demonstrate encouraging results that establish a potential role for allo-HSCT in selected high-risk patients with HL. This trial was registered at www.clinicaltrials.gov as #NCT00908180.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Das-Gupta E, Thomson KJ, Bloor AJC, et al. Allo-HSCT in transplant-naïve patients with Hodgkin lymphoma: a single-arm, multicenter study. Blood Adv. 2019. PMID: 31869413. doi:10.1182/bloodadvances.2019001016

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。